Mohamed Zaki, M.D., Ph.D., has served as ADC Therapeutics' Chief Medical Officer since January 2023. From September 2018 to December 2022 he served in senior clinical development roles at AbbVie, including Vice President & Global Head of Oncology Clinical Development and Vice President & Global Head of Hematology Clinical Development, and from 2010 to 2018 in various senior clinical development roles at Celgene; earlier he worked at Sanofi-Aventis and at Centocor, a subsidiary of Johnson & Johnson. Dr. Zaki holds an M.D. and M.S. from Ain Shams University School of Medicine and a Ph.D. held jointly from the University of Pennsylvania and Ain Shams University.